Seeking Alpha
Profile| Send Message|
( followers)  

Next week is a busy earnings season, with many quarterly earnings releases scheduled and a bunch of stocks to watch. However, my focus is on Biotechnology and Drugs stocks that have earnings due in upcoming weeks and these stocks are selected based on popularity, volume and more importantly, a significant price change expected based on the earning results and forecast.

In this article, I will focus on the second set of nine stocks. This article provides earnings previews on several stocks to consider in anticipation of their earnings reports. Use this list as a potential starting point for your analysis.

Mylan Inc. (MYL): April 26, 2012

Mylan Inc. (Mylan) is a pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan is focused on respiratory, allergy and psychiatric therapies.

Mylan has a market cap of $9.45 billion and will report its first-quarter earnings results on April 26, 2012, before the market open. First-quarter revenue is expected to be $1.58 billion compared with $1.45 billion for the same quarter last year. Earnings per share for the first quarter are expected to be 51 cents from 44 cents in the year-ago period. Mylan is currently trading around $22.07 with a 52-week range of $15.49 to $25.46.

Regeneron Pharmaceuticals Inc (REGN): April 26, 2012

Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA™ (aflibercept) Injection. Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP (aflibercept) Concentrate for Intravenous Infusion.

Regeneron has a market cap of $11.51 billion and will report its first-quarter earnings results on April 26, 2012, before the market open. First-quarter revenue is expected to be $170.11 million compared with $112.20 million for the same quarter last year. Earnings per share for the first quarter are expected to be a loss of 26 cents from a loss of 49 cents in the year-ago period. Regeneron is currently trading around $122.6 with a 52-week range of $42.83 to $124.49.

AstraZeneca plc (ADR) (AZN): April 26, 2012

AstraZeneca PLC is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation.

AstraZeneca has a market cap of $56.24 billion and will report its first-quarter earnings results on April 26, 2012, before the market open. First-quarter revenue is expected to be $7.88 billion compared with $8.29 billion for the same quarter last year. Earnings per share for the first quarter are expected to be $1.8 from $2.23 a share in the year-ago period. AstraZeneca is currently trading around $44.22 with a 52-week range of $40.89 to $52.54.

Gilead Sciences, Inc. (GILD): April 26, 2012

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions.

Gilead Sciences has a market cap of $34.47 billion and will report its first-quarter earnings results on April 26, 2012, after the market close. First-quarter revenue is expected to be $2.20 billion compared with $1.93 billion for the same quarter last year. Earnings per share for the first quarter are expected to be 94 cents from 87 cents in the year-ago period. Gilead Sciences is currently trading around $45.51 with a 52-week range of $34.45 to $56.50.

Vertex Pharmaceuticals Incorporated (VRTX): April 26, 2012

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. The company's two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus (HCV), infection, and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis.

Vertex Pharmaceuticals has a market cap of $7.68 billion and will report its first-quarter earnings results on April 26, 2012, after the market close. First-quarter revenue is expected to be $473.37 million compared with $73.66 million for the same quarter last year. Earnings per share for the first quarter are expected to be 65 cents from a loss of 87 cents in the year-ago period. Vertex Pharmaceuticals is currently trading around $36.17 with a 52-week range of $26.50 to $58.87.

BioMarin Pharmaceutical Inc. (BMRN): April 26, 2012

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. Its product portfolio includes four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

BioMarin Pharmaceutical has a market cap of $3.79 billion and will report its first- quarter earnings results on April 26, 2012, after the market close. First-quarter revenue is expected to be $118.79 million compared with $109.46 million for the same quarter last year. Earnings per share for the first quarter are expected to be a loss of 15 cents from a loss of 4 cents a share in the year-ago period. BioMarin Pharmaceutical is currently trading around $32.74 with a 52-week range of $23.74 to $38.95.

Merck & Co., Inc. (MRK): April 27, 2012

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates in four segments: Pharmaceutical, Animal Health, Consumer Care and Alliances.

Merck has a market cap of $114.95 billion and will report its first-quarter earnings results on April 27, 2012, before the market open. First-quarter revenue is expected to be $11.83 billion compared with $11.58 billion for the same quarter last year. Earnings per share for the first quarter are expected to be 97 cents from 92 cents in the year-ago period. Merck is currently trading around $37.78 with a 52-week range of $29.47 to $39.43.

ImmunoGen, Inc. (IMGN): April 27, 2012

ImmunoGen, Inc. is focused on the development of antibody-based anticancer therapeutics . The company develops targeted therapeutics for the treatment of cancer, and the design of linkers that enable these agents to be attached to the antibodies while in the blood stream and released in their fully active form after delivery to a cancer cell. The product candidates developed by the company and through its collaborations with others utilize its Targeted Antibody Payload ((NYSE:TAP)) technology. Its TAP technology is designed to enable the creation of anticancer products.

ImmunoGen, Inc. has a market cap of $946.38 million and will report its first-quarter earnings results on April 27, 2012, before the market open. First-quarter revenue is expected to be $4.24 million compared with $5.21 million for the same quarter last year. Earnings per share for the first quarter are expected to be a loss of 25 cents from a loss of 22 cents in the year-ago period. ImmunoGen, Inc. is currently trading around $12.33 with a 52-week range of $9.17 to $16.20.

Pfizer Inc. (PFE): May 1, 2012

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health and Consumer Healthcare, and Nutrition.

Pfizer has a market cap of $164.69 billion and will report its first-quarter earnings results on May 1, 2012, before the market open. First-quarter revenue is expected to be $15.47 billion compared with $16.50 billion for the same quarter last year. Earnings per share for the first quarter are expected to be 56 cents from 60 cents in the year-ago period. Pfizer is currently trading around $21.85 with a 52-week range of $16.63 to $22.80.

Sources: Some of the data is sourced from Google Finance, Yahoo Finance and investors site.


Disclosure: I have no positions in any stocks mentioned, but may initiate a long position in MYL, REGN, VRTX, BMRN, AZN, GILD, IMGN, MRK, PFE over the next 72 hours.

Disclaimer: I am not a registered investment advisor and do not provide specific investment advice. The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research and reach your own conclusion. It is up to the investors to make the correct decision after necessary research.

Source: Biotechnology And Drugs Stocks To Watch Ahead Of Earnings (Part 2)